Epigenetic regulation of the human p53 gene promoter by the CTCF transcription factor in transformed cell lines

Oncogene
E Soto-Reyes, Félix Recillas-Targa

Abstract

Epigenetic silencing of tumor suppressor gene promoters has become a more frequent phenomenon in cancer than previously anticipated. In this study we addressed the mechanisms involved in the protection of the p53 tumor suppressor gene against epigenetic silencing in human transformed cell lines. We characterized a binding site for the CCCTC-binding factor (CTCF) in the human p53 gene promoter that contributes to its transcriptional expression, and has the ability to maintain this regulatory element in a local open chromatin configuration. In the absence of CTCF we observe the incorporation of repressive histone marks, such as H3K9me3, H3K27me3 and H4K20me3, in different sub-domains of the upstream regulatory sequence. This evidence suggests that CTCF protects the p53 gene promoter against repressive histone marks. Notably, no apparent direct correlation between repression and DNA hypermethylation has been detected. Together, we present evidence supporting the relevant role of CTCF in the epigenetic regulation of tumor suppressor genes and cancer. We propose that CTCF is a strategic component responsible for the maintenance and segregation of epigenetic traits.

References

Aug 23, 2001·Proceedings of the National Academy of Sciences of the United States of America·T SawadoM Groudine
Aug 23, 2002·Seminars in Cancer Biology·Elena M KlenovaVictor V Lobanenkov
Sep 25, 2003·Cellular and Molecular Life Sciences : CMLS·F Antequera
Feb 26, 2004·Nucleic Acids Research·Viviana Valadez-GrahamFélix Recillas-Targa
May 18, 2004·Genes & Development·Gunnar SchottaThomas Jenuwein
Sep 14, 2004·Nature Genetics·Wenqiang YuRolf Ohlsson
Dec 2, 2004·Nature Reviews. Cancer·Jean-Pierre Issa
Jul 19, 2005·Acta Neuropathologica·Vishwa Jeet AmatyaHiroko Ohgaki
Sep 5, 2006·Molecular Cell·Ko IshiharaMitsuyoshi Nakao
Sep 23, 2006·Journal of Cellular and Molecular Medicine·Felix Recillas-TargaLuis Benítez-Bribiesca
Oct 31, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Darci T Butcher, David I Rodenhiser
Feb 27, 2007·Cell·Peter A Jones, Stephen B Baylin
Mar 17, 2007·Cancer Research·Inti A De La Rosa-VelázquezFélix Recillas-Targa
Apr 5, 2007·Nature Protocols·Susan J ClarkMarianne Frommer
Oct 24, 2007·Current Topics in Developmental Biology·Galina N Filippova
Nov 7, 2007·Molecular and Cellular Biology·Martín Escamilla-Del-Arenal, Félix Recillas-Targa
Mar 19, 2008·The Journal of Experimental Medicine·Adam Williams, Richard A Flavell
Jul 5, 2008·Nature·Alexander MeissnerEric S Lander
Oct 22, 2008·Molecular and Cellular Biology·Chia-Hsin SuMing-Ta Hsu
Dec 2, 2008·Nature Reviews. Drug Discovery·Alexei VazquezGareth L Bond
Mar 3, 2009·Molecular Cell·Salah MahmoudiMarianne Farnebo
Mar 19, 2009·Genes & Development·Minh T N LeBing Lim
May 5, 2009·Cell·Karen H Vousden, Carol Prives
Sep 10, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·France DocquierElena Klenova

❮ Previous
Next ❯

Citations

Sep 8, 2012·Genome Research·Hao WangJohn A Stamatoyannopoulos
Aug 19, 2011·Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire·Félix Recillas-TargaErnesto Soto-Reyes
Jun 15, 2011·BMC Cancer·Mercedes Dávalos-SalasFélix Recillas-Targa
Jan 27, 2012·BMC Cancer·Ernesto Soto-ReyesLuis A Herrera
Dec 16, 2011·Journal of Translational Medicine·Rosalia de Necochea-CampionEwa Carrier
Jul 4, 2012·International Journal of Molecular Sciences·Chen-Feng QiHerbert C Morse
Oct 9, 2014·Nucleic Acids Research·Oliver WethRainer Renkawitz
Jan 31, 2012·Cytogenetic and Genome Research·A Hernández-HernándezF Recillas-Targa
Jan 24, 2016·Current Opinion in Genetics & Development·Tamer AliMarek Bartkuhn
Feb 24, 2016·American Journal of Human Genetics·Xing HuaJianxin Shi
Nov 1, 2011·Journal of Genetics and Genomics = Yi Chuan Xue Bao·Can ZhangLei Zhou
Jul 22, 2015·Biochimica Et Biophysica Acta·Elena GrossiMaite Huarte
Oct 8, 2015·Scientific Reports·Georgina Victoria-AcostaJorge Melendez-Zajgla
Apr 5, 2013·International Journal of Cancer. Journal International Du Cancer·Jessamy C TiffenJohn E J Rasko
Apr 6, 2011·Journal of Cellular Physiology·Francesco Paolo Fiorentino, Antonio Giordano
Mar 18, 2016·BMC Cancer·Erandi Ayala-OrtegaFélix Recillas-Targa
Oct 10, 2013·Journal of Cellular Physiology·Sabita N Saldanha, Trygve O Tollefsbol
Jul 4, 2015·Aging Cell·Reuben H KimNo-Hee Park
Aug 11, 2015·Cell Reports·Matthew T MauranoJohn A Stamatoyannopoulos
Apr 18, 2016·Biochimica Et Biophysica Acta·Anna KazanetsMichael Witcher
Dec 31, 2011·Epigenetics : Official Journal of the DNA Methylation Society·Rodrigo González-BarriosLuis A Herrera
Mar 31, 2011·Mutation Research·Cátia Lira Do AmaralLusânia Maria Greggi Antunes
Jun 12, 2016·Briefings in Functional Genomics·Veronique G LeBlanc, Marco A Marra
Oct 19, 2016·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Ji-Yeon KimYeon Hee Park
Mar 21, 2017·Oncogene·A D MarshallJ E J Rasko
Sep 21, 2018·Leukemia & Lymphoma·Giovanni D'ArenaVitalba Ruggieri
Apr 6, 2019·Current Drug Targets·Maryam Zanjirband, Soheila Rahgozar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.